Targeting triple-negative breast cancer: optimising therapeutic outcomes

被引：143

作者：

Gelmon, K. ^{[1
,2
]}

Dent, R. ^{[3
,4
]}

Mackey, J. R. ^{[5
,6
]}

Laing, K. ^{[7
,8
]}

McLeod, D. ^{[9
]}

Verma, S. ^{[10
,11
]}

机构：

[1] Univ British Columbia, Dept Med, Vancouver, BC V5Z 4E6, Canada

[2] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada

[3] Natl Canc Ctr, Singapore, Singapore

[4] Duke NUS Grad Med Sch Singapore, Off Clin Sci, Singapore, Singapore

[5] Univ Alberta, Dept Oncol, Edmonton, AB, Canada

[6] Cross Canc Inst, Dept Med Oncol, Edmonton, AB T6G 1Z2, Canada

[7] Mem Univ Newfoundland, Dept Med, St John, NF, Canada

[8] Eastern Hlth, Canc Care Program, St John, NF, Canada

[9] Kaleidoscope Strateg, Toronto, ON, Canada

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Sunnybrook Hlth Sci Ctr, Dept Med, Div Med Oncol Hematol, Toronto, ON M4N 3M5, Canada

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 09期

关键词：

basal like; breast cancer; cancer treatment; targeted therapy; triple negative; systematic review; PACLITAXEL PLUS BEVACIZUMAB; ENDOTHELIAL GROWTH-FACTOR; BASAL-LIKE SUBTYPE; PHASE-II; PROGESTERONE-RECEPTOR; NEOADJUVANT CHEMOTHERAPY; PRECLINICAL MODELS; 1ST-LINE TREATMENT; ESTROGEN-RECEPTOR; RANDOMIZED-TRIAL;

D O I：

10.1093/annonc/mds067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC) defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2. It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC. A systematic review of PubMed and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with targeted and platinum-based therapies. Our review identified TNBC studies of agents with different mechanisms of action, including induction of synthetic lethality and inhibition of angiogenesis, growth, and survival pathways. Combining targeted agents with chemotherapy in TNBC produced only modest gains in progression-free survival, and had little impact on survival. Six TNBC subgroups have been identified and found to differentially respond to specific targeted agents. The use of biological preselection to guide therapy will improve therapeutic indices in target-bearing populations. Ongoing clinical trials of targeted agents in unselected TNBC populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target-selected populations.

引用

页码：2223 / 2234

页数：12

共 119 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2]

Alba E, 2011, J CONTRACEPT FERTIL, P29

[3] Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab [J].

Andre, Fabrice ;

Campone, Mario ;

O'Regan, Ruth ;

Manlius, Corinne ;

Massacesi, Cristian ;

Sahmoud, Tarek ;

Mukhopadhyay, Pabak ;

Soria, Jean-Charles ;

Naughton, Michael ;

Hurvitz, Sara A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5110-5115

[4]

[Anonymous], CANC RES

[5] Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer [J].

Atchley, Deann P. ;

Albarracin, Constance T. ;

Lopez, Adriana ;

Valero, Vicente ;

Amos, Christopher I. ;

Gonzalez-Angulo, Ana Maria ;

Hortobagyi, Gabriel N. ;

Arun, Banu K. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4282-4288

[6] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer [J].

Barrios, Carlos H. ;

Liu, Mei-Ching ;

Lee, Soo Chin ;

Vanlemmens, Laurence ;

Ferrero, Jean-Marc ;

Tabei, Toshio ;

Pivot, Xavier ;

Iwata, Hiroji ;

Aogi, Kenjiro ;

Lugo-Quintana, Roberto ;

Harbeck, Nadia ;

Brickman, Marla J. ;

Zhang, Ke ;

Kern, Kenneth A. ;

Martin, Miguel .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) :121-131

[7] First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer [J].

Baselga, J. ;

Bradbury, I. ;

Eidtmann, H. ;

Di Cosimo, S. ;

Aura, C. ;

De Azambuja, E. ;

Gomez, H. ;

Dinh, P. ;

Fauria, K. ;

Van Dooren, V. ;

Paoletti, P. ;

Goldhirsch, A. ;

Chang, T-W ;

Lang, I. ;

Untch, M. ;

Gelber, R. D. ;

Piccart-Gebhart, M. .

CANCER RESEARCH, 2010, 70

[8]

Baselga J, 2009, CANC RES

[9] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[10]

Bear HD, 2011, J CONTRACEPT FERTIL, P29

← 1 2 3 4 5 6 7 8 9 10 →